SG11201400879SA - Anti-tumor necrosis factor-alpha agents and uses thereof - Google Patents

Anti-tumor necrosis factor-alpha agents and uses thereof

Info

Publication number
SG11201400879SA
SG11201400879SA SG11201400879SA SG11201400879SA SG11201400879SA SG 11201400879S A SG11201400879S A SG 11201400879SA SG 11201400879S A SG11201400879S A SG 11201400879SA SG 11201400879S A SG11201400879S A SG 11201400879SA SG 11201400879S A SG11201400879S A SG 11201400879SA
Authority
SG
Singapore
Prior art keywords
necrosis factor
tumor necrosis
alpha agents
alpha
agents
Prior art date
Application number
SG11201400879SA
Inventor
Aires Da Silva Frederico Nuno Castanheira
Côrte-Real Sofia Volker
Silva Albuquerque E Freitas Rui Pedro Da
Llorente Grancho Lourenço Sara Ferreira
Original Assignee
Technophage Investigação E Desenvolvimento Em Biotecnologia Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investigação E Desenvolvimento Em Biotecnologia Sa filed Critical Technophage Investigação E Desenvolvimento Em Biotecnologia Sa
Publication of SG11201400879SA publication Critical patent/SG11201400879SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201400879SA 2011-09-23 2012-09-19 Anti-tumor necrosis factor-alpha agents and uses thereof SG11201400879SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538548P 2011-09-23 2011-09-23
PCT/PT2012/000035 WO2013043070A2 (en) 2011-09-23 2012-09-19 Anti-tumor necrosis factor-alpha agents and uses thereof

Publications (1)

Publication Number Publication Date
SG11201400879SA true SG11201400879SA (en) 2014-04-28

Family

ID=47146619

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201400879SA SG11201400879SA (en) 2011-09-23 2012-09-19 Anti-tumor necrosis factor-alpha agents and uses thereof
SG10201504605RA SG10201504605RA (en) 2011-09-23 2012-09-19 Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201504605RA SG10201504605RA (en) 2011-09-23 2012-09-19 Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof

Country Status (9)

Country Link
US (2) US9399678B2 (en)
EP (1) EP2758434A2 (en)
JP (1) JP2014530001A (en)
CN (1) CN103906765A (en)
AU (1) AU2012310328A1 (en)
BR (1) BR112014006929A2 (en)
CA (1) CA2849409A1 (en)
SG (2) SG11201400879SA (en)
WO (1) WO2013043070A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012310328A1 (en) * 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
DE102014112212A1 (en) * 2014-08-26 2016-03-03 Akesion Gmbh Recombinant fusion proteins for the prevention or treatment of adhesions in tissues or organs
CA3016686A1 (en) * 2015-03-09 2016-09-15 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction
MX2018009499A (en) 2016-02-05 2019-05-06 Univ Texas Egfl6 specific monoclonal antibodies and methods of their use.
AU2018241241A1 (en) * 2017-03-27 2019-11-07 Garvan Institute Of Medical Research Screening methods
JP2020530453A (en) 2017-08-09 2020-10-22 マサチューセッツ インスティテュート オブ テクノロジー Albumin-binding peptide bond and its method
CN110066337B (en) * 2019-05-16 2022-06-21 艾柏森(江苏)生物科技有限公司 anti-TNF-alpha antibody
AU2020470781A1 (en) * 2020-10-01 2023-05-18 Immunicom, Inc. Reduced leaching of a ligand
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
SE509359C2 (en) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0550436A1 (en) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
SE9002213D0 (en) 1990-06-21 1990-06-21 Hightech Receptor Ab ALBUMIN BINDING PROTEINS
FI85768C (en) 1990-07-04 1992-05-25 Valtion Teknillinen FOERFARANDE FOER UTFOERNING AV YTPLASMONRESONANSMAETNING SAMT I FOERFARANDET ANVAENDBAR GIVARE.
DE69110032T2 (en) 1991-06-08 1995-12-21 Hewlett Packard Gmbh Method and device for determining and / or determining the concentration of biomolecules.
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5643570A (en) 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
US6962686B2 (en) 1994-10-12 2005-11-08 California Institute Of Technology Cell-specific gene delivery vehicles
DE69630514D1 (en) 1995-01-05 2003-12-04 Univ Michigan SURFACE-MODIFIED NANOPARTICLES AND METHOD FOR THEIR PRODUCTION AND USE
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2258817T3 (en) * 1997-05-21 2006-09-01 Biovation Limited METHOD FOR THE PRODUCTION OF NON-IMMUNOGEN PROTEINS.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
JP2002518663A (en) 1998-05-20 2002-06-25 グラッフィニティ ファルマシューティカル デザイン ゲーエムベーハー SPR sensor for simultaneous measurement of many samples existing in liquid state
US6289286B1 (en) 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
US6319691B1 (en) 1999-06-15 2001-11-20 Usa Universe Bioengineering, Inc. Fusion proteins comprising IFN-alpha2b and TM-alpha1
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
JP2006512895A (en) * 2002-06-28 2006-04-20 ドマンティス リミテッド Ligand
EP1732613A2 (en) 2004-04-06 2006-12-20 Affibody AB Use of serum albumin binding peptides conjugates for the preparation of a medicament
MX363423B (en) 2005-05-18 2019-03-22 Ablynx Nv Improved nanobodies against tumor necrosis factor-alpha.
US7846439B2 (en) * 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
WO2010017595A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Variant domain antibodies
MX345226B (en) 2008-10-29 2017-01-20 Ablynx Nv Formulations of single domain antigen binding molecules.
US20110195396A1 (en) 2010-02-10 2011-08-11 Selinfreund Richard H Chewable compositions for the stabilization of diagnostic biomarkers
JP6130350B2 (en) * 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． Methods of treating immune disorders with single domain antibodies against TNFα
AU2012310328A1 (en) * 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof

Also Published As

Publication number Publication date
EP2758434A2 (en) 2014-07-30
WO2013043070A2 (en) 2013-03-28
WO2013043070A3 (en) 2013-07-25
SG10201504605RA (en) 2015-07-30
AU2012310328A1 (en) 2014-04-10
WO2013043070A9 (en) 2014-05-08
US20150037349A1 (en) 2015-02-05
CA2849409A1 (en) 2013-03-28
US9399678B2 (en) 2016-07-26
BR112014006929A2 (en) 2017-04-04
AU2012310328A2 (en) 2014-05-22
US20170137510A1 (en) 2017-05-18
CN103906765A (en) 2014-07-02
JP2014530001A (en) 2014-11-17

Similar Documents

Publication Publication Date Title
HUS2100012I1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
IL233051B (en) Anti-phf-tau-antibodies and their uses
HK1198433A1 (en) N-acyldipeptide derivatives and their uses n-
EP2681843A4 (en) Delay circuitry
PL2686331T3 (en) Rebaudioside b and derivatives
EP2774512A4 (en) Chair
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EP2774511A4 (en) Chair
SG11201400879SA (en) Anti-tumor necrosis factor-alpha agents and uses thereof
HK1184661A1 (en) Chair
IL229844B (en) Anti-psgl-1-antibodies and uses thereof
GB201110783D0 (en) Methods and uses
GB201116774D0 (en) Uses and methods
ZA201308892B (en) Compositions and methods
EP2766357A4 (en) Meso-biliverdin compositions and methods
EP2693879A4 (en) Migrastatins and uses thereof
GB2488222B (en) Chair
HK1179132A1 (en) Chair
GB201108490D0 (en) Methods and uses
ME03310B (en) 4 - imidazopyridazin- 1-yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
GB201116340D0 (en) Compositions and methods
IL215970A0 (en) Adjustable sink
GB201119948D0 (en) Corben chair 001-103
AU339945S (en) Chair